What’s surprising is the drug in question. Li has been dosing the mice with one of the GLP-1 agonist drugs—the ​​suddenly-everywhere class of drugs that includes Ozempic, Wegovy, and Mounjaro. Originally designed to treat diabetes and help with weight loss, GLP-1 (glucagon-like peptide 1) agonists are being tested against a number of diseases as scientists explore their wide-ranging effects—and pharmaceutical companies look to make even more profits from the burgeoning wonder drugs.